| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A randomised phase III study of bevacizumab and carboplatin–pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial
|
Felip, E.
|
|
|
36 |
5 |
p. 548-560
|
artikel
|
| 2 |
Comment on: A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial
|
Meyer, J.
|
|
|
36 |
5 |
p. 601
|
artikel
|
| 3 |
Editorial Board
|
|
|
|
36 |
5 |
p. iii
|
artikel
|
| 4 |
Efficacy assessment in phase I clinical trials: endpoints and challenges
|
Gouda, M.A.
|
|
|
36 |
5 |
p. 507-519
|
artikel
|
| 5 |
Enhancing radiotherapy with PARP inhibition in soft-tissue sarcomas: a promising synergy requiring specific attention to normal tissues?
|
Levy, A.
|
|
|
36 |
5 |
p. 488-490
|
artikel
|
| 6 |
FOxTROT: is anti-EGFR a good dancing partner?
|
Montagut, C.
|
|
|
36 |
5 |
p. 475-477
|
artikel
|
| 7 |
Going forward in pleural mesothelioma: time for a shift from a single-entity treatment approach
|
Hayashi, H.
|
|
|
36 |
5 |
p. 478-480
|
artikel
|
| 8 |
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Vogel, A.
|
|
|
36 |
5 |
p. 491-506
|
artikel
|
| 9 |
Lessons from TROPiCS-04: ‘safety-first’ for success in late-stage clinical trials
|
Ong, M.
|
|
|
36 |
5 |
p. 481-483
|
artikel
|
| 10 |
Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population ☆
|
Seligmann, J.F.
|
|
|
36 |
5 |
p. 520-528
|
artikel
|
| 11 |
Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials
|
Dal Pra, A.
|
|
|
36 |
5 |
p. 572-582
|
artikel
|
| 12 |
Reply to Letter to the Editor: ‘A phase III randomised trial on the addition of a contact x-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 years results of the OPERA trial’ by J. Meyer, T. Koessler
|
Baron, D.
|
|
|
36 |
5 |
p. 601-602
|
artikel
|
| 13 |
Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib
|
Horinouchi, H.
|
|
|
36 |
5 |
p. 583-591
|
artikel
|
| 14 |
Results of a phase Ib study of olaparib with concomitant radiotherapy in soft-tissue sarcoma: a French sarcoma group study
|
Sargos, P.
|
|
|
36 |
5 |
p. 592-600
|
artikel
|
| 15 |
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
|
Powles, T.
|
|
|
36 |
5 |
p. 561-571
|
artikel
|
| 16 |
Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials
|
Williams, H.
|
|
|
36 |
5 |
p. 543-547
|
artikel
|
| 17 |
Table of Contents
|
|
|
|
36 |
5 |
p. i-ii
|
artikel
|
| 18 |
Telisotuzumab vedotin and osimertinib: the METamorphosis of epidermal growth factor receptor-mutant lung cancer?
|
Remon, J.
|
|
|
36 |
5 |
p. 484-487
|
artikel
|
| 19 |
The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study
|
Rangelova, E.
|
|
|
36 |
5 |
p. 529-542
|
artikel
|
Tijdschrift beschrijving